{
  "CODEINE": {
    "CYP2D6": {
      "UM": "Avoid codeine due to increased risk of morphine toxicity (use alternative analgesic)",
      "PM": "Avoid codeine due to lack of efficacy (consider alternative analgesic)",
      "IM": "Consider alternative analgesic or monitor closely",
      "NM": "Standard dosing"
    }
  },
  "CLOPIDOGREL": {
    "CYP2C19": {
      "PM": "Use alternative antiplatelet agent (e.g., prasugrel or ticagrelor) due to reduced effectiveness",
      "IM": "Consider alternative therapy or enhanced monitoring",
      "NM": "Standard dosing",
      "RM": "Standard dosing"
    }
  },
  "WARFARIN": {
    "CYP2C9": {
      "PM": "Initiate with lower maintenance dose and use genotype-informed dosing algorithms; increase monitoring of INR",
      "IM": "Consider moderate dose reduction and close INR monitoring",
      "NM": "Standard dosing"
    }
  },
  "SIMVASTATIN": {
    "SLCO1B1": {
      "LowFunction": "Use lower dose or consider alternative statin (increased myopathy risk)",
      "NormalFunction": "Standard dosing"
    }
  },
  "AZATHIOPRINE": {
    "TPMT": {
      "PM": "Avoid azathioprine or greatly reduce starting dose; consider alternative therapy",
      "IM": "Start at reduced dose (e.g., 30%-70% of standard) with careful monitoring",
      "NM": "Standard dosing"
    }
  },
  "FLUOROURACIL": {
    "DPYD": {
      "PM": "Avoid fluoropyrimidines or use alternative therapy due to high risk of severe toxicity",
      "IM": "Reduce dose (often 25%-50% depending on activity score) and monitor closely",
      "NM": "Standard dosing"
    }
  }
  
}
